Acute Myeloid Leukemia (AML) is a rapid-progressing hematologic malignancy characterized by the uncontrolled proliferation of immature myeloid cells. Current cancer research focuses on understanding the genetic and molecular basis of AML to develop targeted therapies. Advances in genomics have identified mutations in genes such as FLT3, NPM1, and DNMT3A, providing insights into disease pathogenesis and potential therapeutic targets. Novel treatments, including FLT3 inhibitors and immune-based therapies like monoclonal antibodies and CAR-T cells, are under investigation. Additionally, researchers are exploring the role of the bone marrow microenvironment in AML progression and resistance to therapy, aiming to improve patient outcomes through personalized medicine.
Title :
Pietro Salvatori, Private Practice, Italy
Title :
Jianhua Luo, University of Pittsburgh, United States
Title :
Marika Crohns, Sanofi, Germany
Title : RNA binding proteins in the pathogenesis of pediatric cancer
Atif A Ahmed, University of Washington-Seattle Children’s Hospital, United States
Title : A novel mRNA genomic technology for precision medicine, early cancer diagnosis, prognosis, treatment follow-up and cancer gene therapy
Rajvir Dahiya, University of California San Francisco, United States
Title : The future of pharmacogenetic polymorphism, pharmacogenomics and pharmamicrobiome in cancer treatment
Bene Ekine-Afolabi, University of East London, United Kingdom